Association between the dosage and duration of statin treatment with coronary collateral development

Coronary Artery Disease

Volumn 17, Issue 6, 2006, Pages 561-565

  Dincer, Irem ^a,b   Ongun, Aydan ^a   Turhan, Sibel ^a   Ozdol, Cagdas ^a   Kumbasar, Deniz ^a   Erol, Cetin ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b Department of Cardiology ^*  (Turkey)

Author keywords

Angiogenesis; Coronary angiography; Coronary artery disease; HMG CoA reductase inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANGIOGENESIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY COLLATERAL CIRCULATION; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEART EJECTION FRACTION; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; STABLE ANGINA PECTORIS; STATISTICAL ANALYSIS; TREATMENT DURATION;

COLLATERAL CIRCULATION; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; RETROSPECTIVE STUDIES;

EID: 33747176593     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200609000-00010     Document Type: Article

References (25)

1. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21:1712-1719.
2. Sowers RJ. Effects of statin on the vasculature: implications for aggressive lipid management in cardiovascular metabolic syndrome. Am J Cardiol 2003; 91 (suppl):14B-22B.
3. Aikawa M. Effects of statin therapy on vascular dysfunction. Coron Artery Dis 2004; 15:227-233.
4. Rorowski AS, Walsh K. Statin therapy and angiogenesis. Curr Opin Lipidol 2003; 14:599-603.
5. Walter DH, Zeiher AM, Dimmeler S. Effects of statins on endothelium and their contribution to neovascularization by mobilization of endothelial progenitor cells. Coron Artery Dis 2004; 15:235-242.
6. Nishikawa H, Miura S, Zhang B, Shimomura H, Arai H, Tsuchiya Y, Saku K. Pravastatin promotes coronary collateral circulation in patients with coronary artery disease. Coron Artery Dis 2002; 13:377-381.
7. Pourati I, Kimmelstiel C, Rand W, Karas R. Statin use is associated with enhanced collateralization of severely diseased coronary arteries. Am Heart J 2003; 146:876-881.
8. Zbinden S, Brunner N, Wustmann K, Billinger M, Meier B, Seiler C. Effect of statin treatment on coronary collateral flow in patients with coronary artery disease. Heart 2004; 90:448-449.
9. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the Curves Study). Am J Cardiol 1998; 81:582-587.
10. Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol 1985; 5:587-592.
11. Billinger M, Kloos P, Eberli FR, Windecker S, Meier B, Seiler C. Physiologically assessed coronary collateral flow and adverse cardiac ischemic events: a follow up study in 403 patients with coronary artery disease. J Am Coll Cardiol 2002; 40:1545-1550.
12. Hansen JF. Coronary collateral circulation: clinical significance and influence on survival in patients with coronary artery occlusion. Am Heart J 1989; 117:290-295.
13. Habib GB, Heibig J, Forman SA, Brown BG, Roberts R, Terrin ML, Bolli R. Influence of coronary collateral vessels on myocardial infarct size in humans: results of phase I Thrombolysis in Myocardial Infarction (TIMI) trial. The TIMI investigators. Circulation 1991; 83:739-746.
14. Pohl T, Seiler C, Billinger M, Herren E, Wustmann K, Mehta H, et al. Frequency distribution of collateral flow and factors influencing collateral channel development. J Am Coll Cardiol 2001; 38:1872-1878.
15. Kilian JG, Keech A, Adams MR, Celermajer DS. Coronary collateralisation: determinants of adequate distal vessel filling after arterial occlusion. Coron Artery Dis 2002; 13:155-159.
16. Kornowsky R. Collateral formation and clinical variables in obstructive coronary artery disease: the influence of hypercholesterolemia and diabetes mellitus. Coron Artery Dis 2003; 14:61-64.
17. Fujita M, Nakae I, Kihara Y, Hasegawa K, Nohara R, Ueda K, et al. Determinants of collateral development in patients with myocardial infarction. Clin Cardiol 1999; 22:465-471.
18. Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinc H, Ergin A. Effects of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999; 99:2239-2242.
19. Rivard A, Fabre JE, Silver M, Chen D, Murohara T, Kearney M, et al. Age-dependent impairment of angiogenesis. Circulation 1999; 99:111-120.
20. Van Belle E, Rivard A, Chen D, Silver M, Bunting S, Ferrara N, et al. Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation 1997; 96:2667-2674.
21. Kyriakides ZS, Kremastinos DT, Michelakakis NA, Matsakas EP, Demovelis T, Toutouzas PK. Coronary collateral circulation in coronary artery disease and systemic hypertension. Am J Cardiol 1991; 67:687-690.
22. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002; 105:739-745.
23. Urbich C, Dernbach E, Zeiher AM, Dimmeler S. Double-edged role of statins in angiogenesis signaling. Circ Res 2002; 90:737-744.
24. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, et al. HMG-CoA reductase inhibitor mobilizes bone-marrow derived endothelial progenitor cells. J Clin Invest 2001; 108:399-405.
25. Assmus B, Urbich C, Aicher A, Hofmann WK, Haendeler J, Rossig L, et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 2003; 92:1049-1055.